Navigation Links
Vivakor Announces Mechanics of Dividend Distribution
Date:12/8/2009

CORALVILLE, Iowa, Dec. 8 /PRNewswire-FirstCall/ -- Vivakor, Inc. (OTC Bulletin Board: VIVK) today announced the mechanics for how shareholders of record on December 1, 2009 will receive the dividend of shares of common stock of HealthAmerica, Inc. that was previously approved by Vivakor's Board of Directors. HealthAmerica is a private Nevada corporation of which Vivakor owned approximately 84% of the outstanding common shares on the record date. The distribution date will be December 9, 2009, and will be conducted as an "upon surrender" distribution. Each Vivakor shareholder will be entitled to receive one share of HealthAmerica common stock for each share of Vivakor common stock beneficially owned on December 1, 2009. The shares of Health America being distributed shall be recorded in the name of each Vivakor shareholder of record on December 1, 2009 as a journal entry with the transfer agent, Integrity Stock Transfer, located in Las Vegas, Nevada. Any shareholder of Vivakor as of the record date, December 1, 2009, may request a certificate directly from the transfer agent, or may simply request a confirmation that a journal entry of the shares with the transfer agent. No other action is required by the Vivakor shareholders to obtain their shares.

About Vivakor, Inc.

Vivakor(TM) is a biomedical/biotechnology company with transdisciplinary research that develops and acquires products in the fields of molecular medicine, electro-optics, biological handling and natural and formulary compounds, that extend or improve life. More information can be found about Vivakor at www.vivakor.com.

About HealthAmerica, Inc.

HealthAmerica is developing a patented, FDA 510(k) cleared, technology (VIVASlices(TM)) that is expected to enhance the resolution of images resulting from MRI. The underlying algorithm may also be useful in determining blood flow velocity measures in imaged tissues, which would be valuable in accessin
'/>"/>

SOURCE Vivakor, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Vivakor Announces Additions to Board of Directors and Scientific Advisory Board
2. Vivakor Confirms Record Date of Stock Dividend
3. Vivakor, Inc. Announces Stock Dividend
4. The Pittsburgh Life Sciences Greenhouse Announces Additions to Nationally Recognized Executive Program
5. BARDA Announces Modification to Development Approach for Recombinant Protective Antigen Anthrax Vaccines
6. ATS Medical Announces CE Mark Approval for the ATS 3f Enable Bioprosthesis
7. AEterna Zentaris Announces Results from its European Phase 3 Study with Cetrorelix in Benign Prostatic Hyperplasia
8. BioLife Solutions Announces Custom cGMP Manufacturing & License Agreement
9. Stemline Therapeutics Announces Poster Presenting in vivo and Anti-Cancer Stem Cell Activity of SL-401 against Chronic Myeloid Leukemia (CML) at the 51st Annual Meeting of the American Society of Hematology (ASH)
10. Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters Over-Allotment Option
11. Gamida Cell Announces Feasibility Study With Weill Cornell Medical College
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/23/2015)... The Thomas Brain Health Center ... groundbreaking pilot study to see if early Alzheimer’s ... little as three to six months. , The ... medicine—will aggressively target and simultaneously treat the numerous ... brain. These include oxidative stress, neuroinflammation, mitochondrial dysfunction, ...
(Date:4/23/2015)... 23, 2015 WuXi PharmaTech (Cayman) Inc. (NYSE: ... technology platform company serving the pharmaceutical, biotechnology and medical ... and the United States , ... the first quarter of 2015 after the New York ... will be Thursday morning, May 14, 2015 Shanghai time). ...
(Date:4/23/2015)... 2015 Glemser Technologies ... EMC® Enterprise Content Division (ECD) Certified Solution Partner ... Documentum® for Life Sciences Solution Suite . The ... capabilities to provide life sciences companies of all ... The EMC Documentum Solution Suite offers four modules: ...
(Date:4/23/2015)... 23, 2015 ReliantHeart's HeartAssist5® Ventricular Assist ... flow through the device) in real time, and this ... world’s leading provider of Machine to Machine (M2M) communications ... Flow via VADLink.com can be monitored by ... drop in flow below a minimum threshold, the patient ...
Breaking Biology Technology:New Study Looks to Reverse Alzheimer’s Disease 2New Study Looks to Reverse Alzheimer’s Disease 3WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 2WuXi PharmaTech Schedules First-Quarter 2015 Earnings Release 3Glemser Earns Accreditation for Life Sciences Solution Suite 2
... Data Presented Today at American Society of Clinical Oncology ... Therapeutics, Inc. today presented data demonstrating the use of ... cetuximab (ERBITUX(R)) on the colorectal cancer cells of individual ... the 54 primary colorectal cultures tested, eight percent were ...
... of response up to week 26 in moderate to ... infliximab. , , CHICAGO, June 1 New ... the Digestive Disease Week meeting demonstrate that Cimzia(R) (certolizumab ... week 26 for adult patients suffering from moderate to ...
... SOUTH PLAINFIELD, N.J., June 1 PTC Therapeutics, Inc. ... as Vice President of Commercial Operations. In this ... President, Commercial, and will be responsible for PTC,s patient ... reimbursement. , , (Logo: http://www.newscom.com/cgi-bin/prnh/20010919/PTCLOGO ...
Cached Biology Technology:Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 2Laboratory Test May Predict Effectiveness of ERBITUX(R) for Individual Colorectal Cancer Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 2Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 3Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 4Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 5Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 6Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 7Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 8Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 9Cimzia(R) (certolizumab pegol) Provides Long-Term Remission and Response Rates in Infliximab-Refractory Crohn's Patients 10PTC Therapeutics Appoints Clare Kennedy as Vice President of Commercial Operations 2
(Date:4/2/2015)... 2, 2015 In the ... far outperforms the strongest competitors, showing outstanding performance ... the system is capable of a throughput of ... up to be ten times faster than most ... performance.      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ...
(Date:4/1/2015)... OXFORD, Conn. , Apr. 1, 2015  NXT-ID, ... a biometric authentication company focused on the growing mobile ... number of Wocket smart wallets is underway to early ... early access group includes usage at retail outlets including ... CVS Pharmacy. Users report Wocket was accepted at all ...
(Date:3/30/2015)... DUBLIN , Mar. 26, 2015 Research and ... addition of the "Global Gesture Recognition Market in ... The analysts forecast the Global Gesture Recognition market ... 12.8% over the period 2013-2018. Gesture recognition ... respond to different gestures of an individual. Gesture recognition ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4Global Gesture Recognition Market in Automotive Sector Report 2015 - Growing Number of Partnerships 2
... School of Medicine of the University of Southern California ... female sex hormone, activates genes in breast-cancer cells. Greater ... lead to new treatments for the disease. ... Keck School,s Department of Biochemistry and Molecular Biology, was ...
... The TWAS 22nd General Meeting will take place on ... Theoretical Physics (ICTP), home to the Academy,s secretariat. TWAS,s ... by Romain Murenzi, executive director of TWAS; Fernando Quevedo, ... Affairs, Italy; and Jacob Palis, TWAS President, will highlight ...
... PARIS, Nov. 15, 2011 DigitalPersona, ... and endpoint protection solutions, today announced the availability ... biometric device manufacturers and solution providers. FingerJet OEM ... along with fast one-to-many identification and one-to-one verification. ...
Cached Biology News:USC researchers discover key aspect of process that activates breast cancer genes 2TWAS 22nd General Meeting in Trieste 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 2DigitalPersona Announces FingerJet OEM Fingerprint Recognition Software for Biometric Device Manufacturers and Solution Providers 3
...
Ezrin/Radixin/Moesin Antibody...
Smac/DIABLO (mouse) (CT) rabbit polyclonal antibody...
... ADAMTS16 ( Abpromise for all ... Synthetic peptide based on the ... the amino acid sequence is proprietary) ... 170690 SWISS Protein ...
Biology Products: